Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.62 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.62 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.62 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.51 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18122029 | 0.84 | ALDH1A1 (0.55) | MAPK1MAP2K4MAPKAPK2MAPK6FGFR1 | |
| SCHEMBL4032541 | 0.81 | PDPK1 (0.47) | MAPK1MAP2K4MAPKAPK2MAPK6MAPKAPK3 | |
| SCHEMBL4025987 | 0.81 | CHEK1 (0.54) | MAPK1MAP2K4MAPKAPK2MAPK6MAPKAPK3 | |
| SCHEMBL1407409 | 0.80 | MEN1 (0.50) | TNKSPARP1TNKS2GAAKMT2A | |
| SCHEMBL4031966 | 0.78 | ESR1 (0.50) | MAPK1MAP2K4MAPKAPK2MAPK6MAPKAPK3 | |
| SCHEMBL20674199 | 0.76 | AHR (0.44) | MAPK1MAP2K4MAPKAPK2MAPK6GAA | |
| SCHEMBL4200287 | 0.73 | IDO1 (0.71) | MAPK1MAP2K4MAPKAPK2MAPK6MAPKAPK3 | |
| SCHEMBL8404432 | 0.71 | AHR (0.47) | GAAKMT2AALDH1A1MEN1CHEK1 | |
| SCHEMBL29363334 | 0.70 | ATM (0.73) | MAPK1GAAKMT2AALDH1A1MEN1 | |
| SCHEMBL1904310 | 0.70 | ATM (0.73) | MAPK1GAAKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | claimed |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2006-05-25 | — | — | US | claimed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | claimed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | claimed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | MAPK1 857/4885MAP2K4 793/4885MAPKAPK2 1606/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | MAPK1 368/4885MAP2K4 402/4885MAPKAPK2 870/4885 |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | IKBKB, NFKBIA, IKBKG | MAPK1 1596/4885MAP2K4 860/4885MAPKAPK2 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.